Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 4Vemurafenib 4selpercatinib 3dabrafenib 3Specimen Handling 3entrectinib 2cobimetinib 2cabozantinib 2X-Rays 2Iodine-131 2Interviews as Topic 2tremelimumab 1tovorafenib 1spartalizumab 1pembrolizumab 1omipalisib 1lenvatinib 1gallium Ga 68 dotatate 1durvalumab 1copanlisib 1Whole Body Imaging 1Transurethral Resection of Prostate 1Thyrotropin Alfa 1Surveys and Questionnaires 1Sodium Iodide 1Robotic Surgical Procedures 1Postoperative Period 1Phantoms, Imaging 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Sodium Iodide × 1 year × Clear all
NCT01398085 2026-05-07

IoN

University College, London

Phase 2/3 Active not recruiting
504 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡